Are you Dr. Knoblauch?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 46 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Spruce St
1 Maloney Building
Philadelphia, PA 19104Phone+1 215-662-3957- Is this information wrong?
Summary
- Dr. Roland Knoblauch, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001
Certifications & Licensure
PA State Medical License 2004 - 2024
Publications & Presentations
PubMed
- Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.Nahor Haddish-Berhane, Yaming Su, Alberto Russu, Meena Thayu, Roland E Knoblauch, Jaydeep Mehta, John Xie, Eric Gibbs, Yu-Nien Sun, Honghui Zhou> ;Clinical Pharmacology and Therapeutics. 2024 Mar 1
- 10 citationsAmivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.Byoung Chul Cho, Dong-Wan Kim, Alexander I Spira, Jorge E Gomez, Eric B Haura, Sang-We Kim, Rachel E Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee...> ;Nature Medicine. 2023 Oct 1
- 3 citationsImmune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Ai-Di Gu, Alexsandra B Espejo, Michelle Kinder, Curtis A Pettaway, John F Wa...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
- Join now to see all
Press Mentions
FDA Approves Yondelis for Two Common Subtypes of Soft Tissue SarcomaOctober 26th, 2015
